Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Best Available Technology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Best Available Technology. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-001017-61 Sponsor Protocol Number: MO29112 Start Date*: 2014-11-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL)
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) DK (Completed) SK (Prematurely Ended) NL (Completed) FR (Completed) SE (Completed) BE (Completed) GR (Completed) ES (Temporarily Halted) SI (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2021-005005-28 Sponsor Protocol Number: ADENOFERT Start Date*: 2022-11-08
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial featu...
    Medical condition: Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001868-36 Sponsor Protocol Number: SPI-POZ-202 Start Date*: 2018-10-18
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
    Medical condition: Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000814-23 Sponsor Protocol Number: CLDK378A2407 Start Date*: 2015-10-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphom...
    Medical condition: Advanced solid tumors and hematological malignancies with ALK genetic alteration and/or overexpression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Temporarily Halted) CZ (Completed) FR (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004083-21 Sponsor Protocol Number: E7438-G000-101 Start Date*: 2015-02-02
    Sponsor Name:Epizyme, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000562-30 Sponsor Protocol Number: NIVACTOR Start Date*: 2017-09-07
    Sponsor Name:Fondazione GONO
    Full Title: A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refrACTORy Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Medical condition: Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)”
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000625-37 Sponsor Protocol Number: BED-004 Start Date*: 2015-08-28
    Sponsor Name:Blue Earth Diagnostics Limited
    Full Title: A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment
    Medical condition: Prostate cancer with biochemical recurrence after radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003052-36 Sponsor Protocol Number: 19067 Start Date*: 2020-01-06
    Sponsor Name:The University of Nottingham
    Full Title: Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis
    Medical condition: Cystic fibrosis (CF) Non-CF Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-002161-30 Sponsor Protocol Number: 1302.5 Start Date*: 2015-09-07
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Sm...
    Medical condition: Recurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) ES (Completed) DE (Completed) PL (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003593-17 Sponsor Protocol Number: BNT411-01 Start Date*: 2021-02-18
    Sponsor Name:BioNTech SE
    Full Title: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in p...
    Medical condition: Chemotherapy-naïve extensive-stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-000809-36 Sponsor Protocol Number: CAP-IT Start Date*: 2016-09-30
    Sponsor Name:Medical Research Council Clinical Trials Unit at UCL
    Full Title: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial.
    Medical condition: Pneumonia
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000041-14 Sponsor Protocol Number: 269050-80-06-19 Start Date*: 2020-06-19
    Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust
    Full Title: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001462-15 Sponsor Protocol Number: MC-MSC.1/aGvHD Start Date*: 2020-09-24
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refrac...
    Medical condition: Steroid refractory Acute Graft versus host Disease
    Disease: Version SOC Term Classification Code Term Level
    27.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001785-14 Sponsor Protocol Number: STRESS-L Start Date*: 2017-11-09
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)
    Medical condition: Tachycardia in Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10007541 - Cardiac disorders 10043071 Tachycardia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001503-20 Sponsor Protocol Number: MedOPP150(ATRACTIB) Start Date*: 2021-07-30
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGAT...
    Medical condition: Advanced or metastatic triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003304-20 Sponsor Protocol Number: OKHN1006 Start Date*: 2012-07-02
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Randomised Controlled Trial of Intravitreal therapy with Avastin compared to Observation in Patients with Diabetic Ischaemic Macular Oedema ‘The DIME study’
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022983-11 Sponsor Protocol Number: BP25438 Start Date*: 2011-01-24
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type...
    Medical condition: Metastatic colorectal cancer, KRAS wild-type (WT) or mutant, with disease progression after first line treatment with an oxaliplatin-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019395-73 Sponsor Protocol Number: CPJMR0012201 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyal...
    Medical condition: polymyalgia rheumatica
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10036099 Polymyalgia rheumatica PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 21 04:57:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA